In addition, PTEN alterations (loss-of-function mutations or deletions) are present in 7.3% of primary melanomas and 15.2% of metastatic melanomas and lead to constitutive phosphoinositide 3-kinase (PI3K) pathway activation14. The gene discussed is PTEN; the disease is melanoma.